Morphology and Composition of the Inner Limiting Membrane: Species-Specific Variations and Relevance toward Drug Delivery Research

被引：72

作者：

Peynshaert, Karen ^{[1
,2
]}

Devoldere, Joke ^{[1
,2
]}

Minnaert, An-Katrien ^{[1
,2
]}

De Smedt, Stefaan C. ^{[1
,2
]}

Remaut, Katrien ^{[1
,2
]}

机构：

[1] Univ Ghent, Fac Pharmaceut Sci, Lab Gen Biochem & Phys Pharm, Ghent, Belgium

[2] Univ Ghent, Ghent Res Grp Nanomed, Ottergemsesteenweg 460, B-9000 Ghent, Belgium

来源：

CURRENT EYE RESEARCH | 2019年 / 44卷 / 05期

基金：

比利时弗兰德研究基金会;

关键词：

Inner limiting membrane; vitreoretinal interface; viral vector; species variations; nanoparticles; HEPARAN-SULFATE PROTEOGLYCAN; TISSUE-PLASMINOGEN ACTIVATOR; FULL-THICKNESS RETINA; BASEMENT-MEMBRANE; INTRAVITREAL INJECTION; GENE DELIVERY; TRANSFECTION EFFICIENCY; VITREORETINAL JUNCTURE; ALBUMIN NANOPARTICLES; VECTOR TRANSDUCTION;

D O I：

10.1080/02713683.2019.1565890

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

The inner limiting membrane (ILM) represents the structural boundary between the vitreous and the retina, and is suggested to act as a barrier for a wide range of retinal therapies. While it is widely acknowledged that the morphology of the human ILM exhibits regional variations and undergoes age-related changes, insight into its structure in laboratory animals is very limited. Besides presenting a detailed overview of the morphology and composition of the human ILM, this review specifically reflects on the species-specific differences in ILM structure. With these differences in mind, we furthermore summarize the most relevant reports on the barrier role of the ILM with regard to viral vectors, nanoparticles, anti-VEGF medication and stem cells. Overall, this review aims to deliberate on the impact of species-specific ILM variations on drug delivery research as well as to pinpoint knowledge gaps which future basic research should resolve.

引用

页码：465 / 475

页数：11

共 107 条

[1] GFAP-Driven GFP Expression in Activated Mouse Muller Glial Cells Aligning Retinal Blood Vessels Following Intravitreal Injection of AAV2/6 Vectors [J].